# Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors

> **NCT01560260** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 20 (actual)

## Conditions studied

- Carney Complex
- Chondrosarcoma
- Gastrointestinal Stromal Tumor
- Paraganglioma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Linsitinib
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT01560260
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2018-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01560260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01560260, "Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01560260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*